GSK Neuro2020

The world is eager for new medicines to address neurological diseases. This is your chance to join GlaxoSmithKline (GSK) scientists - helping to put your game-changing science on the drug discovery fast track.

Your idea. Our expertise and financial support.

GSK Neuro2020 is your opportunity to win a partnership with GSK - helping to develop new neuroscience medicines from your innovative ideas. This program is designed to encourage partnership between scientists and GSK. You supply the concept. We supply the drug discovery expertise and access to our vast scientific resources.

Is GSK Neuro2020 right for you?

GSK Neuro2020 is an electronic Request-for-Partners (eRFP) Program and is open to scientists working for institutions in China.  You tell us about your concept and our panel of judges evaluates each submission. If your proposal is chosen, a team of GSK scientists will collaborate with you to explore your concept, the same way as we do for internal projects. In short, you and your idea will be on an accelerated drug discovery path to success, with the potential to have a full-blown drug discovery partnership in place by 2020.  

Transform game-changing science to drug discovery through partnering with GSK

The concept is simple but powerful: bring together the insight and creativity of the academic world with the drug discovery expertise of GSK, to establish truly integrated partnerships that can accelerate innovative neuroscience drug discovery. The goal is to translate innovative research into life-changing new medicines for patients who suffer from neurological diseases.   

We are inviting applications from scientists (applicants), located in China, who would welcome an opportunity to collaborate with GSK to transform their game-changing neuroscience research to drug discovery. 

Through GSK Neuro2020, applicants and GSK will establish a partnership to put innovative research ranging from novel concept/hypothesis, target/pathway, tool/probe, assay development, optimization of lead molecules (small molecules, biologics and other modalities) and/or technological platforms, on an accelerated drug discovery path and aim to enable entry to a full-blown drug discovery partnership by 2020. On this collaborative journey, GSK will bring world-class expertise and knowledge in drug discovery to GSK Neuro2020.

The field of neuroscience represents one of the greatest areas of unmet medical need and GSK is particularly interested in the following areas:

• Novel target identification approaches and methodologies, such as (but not limited to) systems pharmacology, bioinformatics (-omics).
• Other technologies that advance neuroscience drug discovery and development, such as biomarkers for disease progression, non-invasive imaging, CNS delivery of small molecules and other modalities.
• Therapeutic hypotheses for the following disease areas:

1. Dementia
2. Brain disorders
3. Aging
4. Pain
5. Stroke
6. Brain / Spinal Traumatic Injury
7. Epilepsy
8. Neuropathy
9. Autism & Schizophrenia

A team of GSK drug discovery scientists will closely collaborate with shortlisted applicants and optimize a plan to transform innovative science to drug discovery. GSK will bring capabilities ranging from drug discovery platforms, technologies and reagents, diversified compound collections and know-how. In addition, GSK brings extensive scientific expertise in utilizing enabling technologies in drug R&D to allow incorporation of the applicant's novel tools or methods into drug discovery.

GSK Neuro2020 will begin by inviting scientists to participate who are working for institutions in China.